Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to receive FDA authorization to test a live bacterial therapeutic, and is a pioneer in the field of LBPs. Our proprietary approach identifies differences between healthy and disease-r...
Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to receive FDA authorization to test a live bacterial therapeutic, and is a pioneer in the field of LBPs. Our proprietary approach identifies differences between healthy and disease-related microbiomes, and leverages beneficial microbes to treat problematic disruptions or ‘dysbioses’.

List your booth number for exhibitions, ask us